m88 casino review Assists in the Conclusion of a more than 0 million Option and License Agreement Between Biocytogen and IDEAYA Biosciences

On July 31, 2024, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, stock code: 02315.HK), an international biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that it had entered into an option m88 casino review license agreement with IDEAYA Biosciences, Inc. (Nasdaq: IDYA). IDEAYA is a clinical-stage precision medicine oncology company.

This agreement grants IDEAYA the option for an exclusive worldwide license from Biocytogen for a potential first-in-class B7H3/PTK7 topo-I-payload BsADC program. B7H3/PTK7 has been found to be co-expressed in multiple solid tumor types, including double-digit percent prevalence in lung, colorectal, head m88 casino review neck cancers.

Under the terms of this agreement, Biocytogen will receive an upfront fee m88 casino review upon an option exercise by IDEAYA, be entitled to receive an option exercise fee, development m88 casino review regulatory milestone payments, commercial milestone payments m88 casino review single-digit royalties on net sales. Total potential upfront, option exercise m88 casino review milestone payments equal an aggregate of USD 406.5 million, including development m88 casino review regulatory milestones of USD 100 million.

m88 casino review was entrusted by Biocytogen to review, modify, and negotiate the agreement for this project. m88 casino review’s efficient and meticulous work style and its dedicated and professional service attitude, earned the trust and recognition of the client.

Partnerm88 sport bettingled m88 casino review’s team in this project.